Pharmaceutical

Purdue debuts opioid-abuse resource

Purdue debuts opioid-abuse resource

By

Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.

Allergan sales rise on "strong" DTC advertising

Allergan sales rise on "strong" DTC advertising

By

Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.

Five things for pharma marketers to know: Thursday, August 6

Five things for pharma marketers to know: Thursday, August 6

By

AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs

Eylea erodes Lucentis, Avastin market share

Eylea erodes Lucentis, Avastin market share

By

Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.

Express Scripts drops Onglyza from 2016 formulary over safety concerns

Express Scripts drops Onglyza from 2016 formulary over safety concerns

By

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

By

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

The MM&M Weekly News Quiz: July 31

The MM&M Weekly News Quiz: July 31

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 31

Five things for pharma marketers to know: Friday, July 31

By

Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment

Turing names J&J vet for chief comms role

Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.

Five things for pharma marketers to know: Wednesday, July 29

Five things for pharma marketers to know: Wednesday, July 29

By

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Therapeutic Focus: Oncology

Therapeutic Focus: Oncology

Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment

FDA approves first PCSK9 inhibitor

FDA approves first PCSK9 inhibitor

By

The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.

The MM&M Weekly News Quiz: July 24

The MM&M Weekly News Quiz: July 24

Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.

BMS US sales are down, despite growing Opdivo adoption

BMS US sales are down, despite growing Opdivo adoption

By

Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.

Five things for pharma marketers to know: Thursday, July 23

Five things for pharma marketers to know: Thursday, July 23

By

Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition

Praluent's FDA review looms, but questions persist

Praluent's FDA review looms, but questions persist

By

A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.

Allergan debuts #ActuallySheCan campaign

Allergan debuts #ActuallySheCan campaign

By

The new campaign seeks to connect with millennial women.

Five things for pharma marketers to know: Monday, July 20

Five things for pharma marketers to know: Monday, July 20

By

Robert Ingram sounds off on drug transparency laws in WSJ op-ed; patients with certain forms of leukemia went into complete remission after taking Amgen's cancer drug; Eli Lilly's future in Alzheimer's disease pinned to new data surfacing this week

Pricing pressure drives pharma collaborations, report says

Pricing pressure drives pharma collaborations, report says

By

The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.

New Sanofi CEO reorganizes company

The restructuring is expected to simplify the drugmaker's organization.

Five things for pharma marketers to know: Monday, July 13

Five things for pharma marketers to know: Monday, July 13

By

Harvoni is now prescribed more than Sovaldi; healthcare group says new hepatitis-C drugs are cost-effective; Roche antibody shrank tumors in certain bladder-cancer patients

Five things for pharma marketers to know: Friday, July 10

Five things for pharma marketers to know: Friday, July 10

By

21st Century Cures legislation passes the House; Novartis's heart-failure drug may launch with "beyond the pill" services; Purdue and GSK are working on using Apple's ResearchKit; the FDA issues warning letter on co-pay card

AdComm Preview: Eli Lilly's lung-cancer drug

AdComm Preview: Eli Lilly's lung-cancer drug

By

An FDA advisory panel will discuss the fate of Lilly's investigational lung-cancer antibody, necitumumab, which improved overall survival incrementally but also had one late-stage trial halted due to an "imbalanced number of deaths" attributed to blood clots.

Insurance trade group says new HCV drugs could cost California billions

An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.

Vertex's Orkambi nabs FDA approval but may face payer backlash

Vertex's Orkambi nabs FDA approval but may face payer backlash

By

The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

By

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

By

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

By

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Studies show blood thinner antidotes work

Clinical trial results for experimental antidotes to oral anticoagulants Pradaxa and Eliquis indicate they reverse blood thinners in a short time.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.